Cyclopharm Appoints New Director With No Current Security Holdings

Cyclopharm Limited ( (AU:CYC) ) just unveiled an update.

Cyclopharm Limited has appointed Douglas Ernest Charles Cubbin as a director effective 4 May 2026, and lodged the required initial director’s interest notice with the ASX. The disclosure confirms that Cubbin currently holds no relevant interests in Cyclopharm securities or related contracts, underscoring regulatory compliance and transparency in the company’s board composition.

The filing indicates that Cubbin is neither a registered holder nor an indirect beneficiary of any Cyclopharm shares or options at the time of appointment. This neutral equity position may be relevant to investors monitoring potential alignment of director incentives with shareholder interests and the evolving governance profile of the company.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australian-listed company in the healthcare sector. It focuses on medical technologies and services, serving clinical and diagnostic markets with a particular emphasis on regulated, publicly disclosed governance structures as required by the ASX.

Average Trading Volume: 129,433

Technical Sentiment Signal: Sell

Current Market Cap: A$91.4M

For a thorough assessment of CYC stock, go to TipRanks’ Stock Analysis page.